Investing in Protalix BioTherapeutics Inc. (PLX): What You Must Know
Protalix BioTherapeutics Inc.’s filing revealed that its PRESIDENT AND CEO Bashan Dror acquired Company’s shares for reported $90484.0 on Oct 19 ’23. In the deal valued at $1.40 per share,64,516 shares were bought. As a result of this transaction, Bashan Dror now holds 132,516 shares worth roughly $0.15 million. H.C. Wainwright reiterated its Protalix BioTherapeutics […]
H.C. Wainwright reiterates Protalix BioTherapeutics Inc. (PLX) rating to a Buy
Protalix BioTherapeutics Inc.’s filing revealed that its PRESIDENT AND CEO Bashan Dror acquired Company’s shares for reported $90484.0 on Oct 19 ’23. In the deal valued at $1.40 per share,64,516 shares were bought. As a result of this transaction, Bashan Dror now holds 132,516 shares worth roughly $0.17 million. H.C. Wainwright reiterated its Protalix BioTherapeutics […]
PLX short interest surges, indicating growing pessimism among investors
Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Protalix BioTherapeutics Inc. shares valued at $90,484 were purchased by Bashan Dror on Oct 19 ’23. At $1.40 per share, Bashan Dror acquired 64,516 shares. The insider’s holdings grew to 132,516 shares worth approximately […]
H.C. Wainwright reiterates Protalix BioTherapeutics Inc. (PLX) rating to a Buy
In a filing, Protalix BioTherapeutics Inc. revealed its PRESIDENT AND CEO Bashan Dror acquired Company’s shares for reported $90484.0 on Oct 19 ’23. In the deal valued at $1.40 per share,64,516 shares were bought. As a result of this transaction, Bashan Dror now holds 132,516 shares worth roughly $0.16 million. H.C. Wainwright reiterated its Protalix […]
Top 5 Robinhood Penny Stocks to Invest In
Penny stocks are a popular investment choice due to high inflation these days. What are we talking about with penny stocks here? Primarily, because they are easy to invest in and are able to make money quickly. Thanks to Robinhood, retail investors have access to the market. As penny stocks break out, you can see […]
Protalix BioTherapeutics Inc. (PLX) stock is falling in premarket, Why is this happening?
Protalix BioTherapeutics, Inc. (NYSE American: PLX) a biopharmaceutical company focused on manufacturing recombinant therapeutic proteins with clinically improved profiles, confirmed receiving a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) concerning the Biologics License Application (BLA) attempting to fast-track approval for use of pegunigalsidase alfa (PRX‑102) for the potential treatment of adults effected […]
